Moreno TLMÁ, Sobrevilla-Calvo PJ

Language: Spanish
References: 14
Page: 28-37
PDF size: 437.45 Kb.

Text Extraction

No abstract

REFERENCES

1. Wagoner SE. Cervical Cáncer. Lancet. 2003;361:2217-25.

2. Saslow D, Philip E, Castle J, et al. American Cancer Society guideline for human pillomavirus (VPH) vaccine use to prevent cervical cancer and its precursors. CA Cancer J clin. 2007;57:7-28.

3. Rambout L, Hopkins L, Hutton Brian, et al. Profilactic vaccination against human papilomavirus infection and disease in women: a systematic review of a randomised controlled trials. CMAJ. 2007;177(5):469-79.

4. Society of Gynecologic Oncologists Education Resource Panel. Cervical cancer prevention in the era of prophylactic vaccines: A preview for gynaecologic oncologists. Gynecologic Oncology. 2006;102;552-62.

5. The Future II Study Group. Quadrivalent Vaccine against Human Papilloma Virus to prevent Hig-Grade Cervical Lesions. N Engl J Med. 2007;356:1915-27.

6. Tovar Guzmán VJ, Ortiz Contreras F, Jiménez Gauna FR, et al. Panorama epidemiológico de la mortalidad por cáncer cervicouterino en México (1980-2004). Rev Fac Med UNAM. 2008;51(2):47-51.

7. García-Carrancá A. Vaccines against human pipllomavirus and perspectives for the prevention and control of cervical cancer. Salud Publica Mex. 2003;45 (Supl 3):S437-S442.

8. Harper DM, Franco EL, Wheeler C, et al. Efficacy of bivalent L1 virus-like particle vaccine in prevention of infection whith human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet. 2004;364:1757-65.

9. Harper D, Franco EL, Wheeler CM, et al. Vaccine Study Group. Sustained efficacy up to 4.5 years of a bivalent L1 viruslike particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomized control trial. Lancet. 2006;367(9518):1247-55.

10. The Future II Study Group. Effect of prophylactic human papillomavirus L1 virus-like particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet. 2007;369:1861-68.

11. Markowitz LE, Eileen FD, Mona S, et al. Quadrivalent Human Papillomavirus Vaccine Recommendations of the Advisory Committee on Immunization Practices (ACIP). CDC. Morbidity and Mortality Weekly Report. 2007;56(March):RR-2.

12. Gutiérrez-Delgado C, Báez-Mendoza C, González-Pier E, et al. Relación costo-efectividad de las intervenciones preventivas contra el cáncer cervical en mujeres mexicanas. Salud Publica Mex. 2008;50:107-18.

13. Tejeda D, Velasco Serrano F, Gómez Pastrana N. Cáncer del cuello uterino. Estado actual de las vacunas frente al virus del papiloma humano (VPH). Oncología. 2007;30(2):42-59.

14. Pollack EA, Balkin M, Edouard L, et al. Ensuring acces to HPV vaccines through integrates services: a reproductive health perspective. Bulletin of the World Health Organization. 2007;85:57-63.